phenylephrine hydrochloride; promethazine hydrochloride
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
PHENERGAN VC is an oral syrup combining phenylephrine hydrochloride (a decongestant) and promethazine hydrochloride (an antihistamine/anticholinergic agent). This fixed-dose combination is indicated for symptomatic relief of upper respiratory conditions, primarily cough and congestion associated with allergies or colds. The phenylephrine acts as a nasal decongestant while promethazine provides antihistamine and anticholinergic effects.
As a mature product approaching loss of exclusivity, the brand team is likely focused on lifecycle extension and defending market share against generic competition in a crowded cough/cold category.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PHENERGAN VC offers limited growth runway; the product is in terminal commercial phase with minimal open job slots. Career value lies in defensive marketing strategy, generic management, and cost optimization—skills directly transferable to other mature products and line extensions.
Worked on PHENERGAN VC at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo